Macrophage delivery of therapeutic nanozymes in a murine model of Parkinsons disease

Nanomedicine

Volumn 5, Issue 3, 2010, Pages 379-396

  Brynskikh, Anna M ^b   Zhao, Yuling ^a,b   Mosley, R Lee ^b   Li, Shu ^a   Boska, Michael D ^b   Klyachko, Natalia L ^c   Kabanov, Alexander V ^a   Gendelman, Howard E ^b   Batrakova, Elena V ^a  

^a UNIVERSITY OF NEBRASKA AT OMAHA   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c MOSCOW STATE UNIVERSITY   (Russian Federation)

Author keywords

Bloodbrain barrier; Catalase; Cell mediated drug delivery; Neuroinflammation; Parkinsons disease

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; CATALASE; CD11B ANTIGEN; GLIAL FIBRILLARY ACIDIC PROTEIN; MACROGOL; POLYETHYLENEIMINE; TYROSINE 3 MONOOXYGENASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BONE MARROW CELL; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; GLIOSIS; MACROPHAGE; MALE; MICELLIZATION; MOUSE; NANOPHARMACEUTICS; NANOTOXICOLOGY; NERVOUS SYSTEM INFLAMMATION; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; SUBSTANTIA NIGRA PARS COMPACTA; SUSTAINED DRUG RELEASE;

ANIMALS; BONE MARROW CELLS; BRAIN; CATALASE; CELL ADHESION; CELL MOVEMENT; DRUG CARRIERS; MACROPHAGES; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; NANOSTRUCTURES; NEUROPROTECTIVE AGENTS; OXIDATIVE STRESS; PARKINSON DISEASE;

EID: 77951235242     PISSN: 17435889     EISSN: None     Source Type: Journal    
DOI: 10.2217/nnm.10.7     Document Type: Article

References (53)

1. Lees Aj, Hardy J, Revesz T: Parkinson's disease. Lancet 373(9680), 2055-2066 (2009).
2. Gonzalez-Polo RA, Soler G, Rodriguezmartin A, Moran JM, Fuentes JM: Protection against MPP neurotoxicity in cerebellar granule cells by antioxidants. Cell. Biol. Int. 28(5), 373-380 (2004). (Pubitemid 38748927)
3. Jain S, Mishra V, Singh P, Dubey PK, Saraf DK, Vyas SP: RGD-anchored magnetic liposomes for monocytes/neutrophils-mediated brain targeting. Int. J. Pharm. 261(1-2), 43-55 (2003). (Pubitemid 36962744)
4. Kao WJ, Liu Y, Gundloori R et al.: Engineering endogenous inflammatory cells as delivery vehicles. J. Control Release 78(1-3), 219-233 (2002). (Pubitemid 34081867)
5. Begley DJ: Delivery of therapeutic agents to the central nervous system: the problems and the possibilities. Pharmacol. Ther. 104(1), 29-45 (2004). (Pubitemid 39410561)
6. Batrakova EV, Li S, Reynolds AD et al.: A macrophage-nanozyme delivery system for Parkinson's disease. Bioconjug. Chem. 18(5), 1498-1506 (2007). (Pubitemid 47464057)
7. Lossinsky AS, Shivers RR: Structural pathways for macromolecular and cellular transport across the blood-brain barrier during inflammatory conditions. Review. Histol. Histopathol. 19(2), 535-564 (2004).
8. Pawlowski NA, Kaplan G, Abraham E, Cohn ZA: The selective binding and transmigration of monocytes through the junctional complexes of human endothelium. J. Exp. Med. 168(5), 1865-1882 (1988). (Pubitemid 19023268)
9. Kuby J: Immunology. Kindt TJ, Goldsby RA, Osborne BA (Eds). WH Freeman WH, NY, USA (1994).
10. Daleke DL, Hong K, Papahadjopoulos D: Endocytosis of liposomes by macrophages: binding, acidification and leakage of liposomes monitored by a new fluorescence assay. Biochim. Biophys. Acta 1024(2), 352-366 (1990). (Pubitemid 20182822)
11. Lee KD, Hong K, Papahadjopoulos D: Recognition of liposomes by cells: in vitro binding and endocytosis mediated by specific lipid headgroups and surface charge density. Biochim. Biophys. Acta 1103(2), 185-197 (1992).
12. Nishikawa K, Arai H, Inoue K: Scavenger receptor-mediated uptake and metabolism of lipid vesicles containing acidic phospholipids by mouse peritoneal macrophages. J. Biol. Chem. 265(9), 5226-5231 (1990). (Pubitemid 20117177)
13. Fujiwara M, Baldeschwieler JD, Grubbs RH: Receptor-mediated endocytosis of poly(acrylic acid)-conjugated liposomes by macrophages. Biochim. Biophys. Acta 1278(1), 59-67 (1996). (Pubitemid 26042271)
14. Nguyen HK, Lemieux P, Vinogradov SV et al.: Evaluation of polyether-polyethyleneimine graft copolymers as gene transfer agents. Gene Ther. 7(2), 126-138 (2000). (Pubitemid 30088959)
15. Vinogradov S, Bronich T, Kabanov A: Self-assembly of polyamine- poly(ethylene glycol) copolymers with phosphorothioate oligonucleotides Bioconjugate Chemistry 9(6), 805-812 (1998). (Pubitemid 28542249)
16. Dou H, Destache CJ, Morehead JR et al.: Development of a macrophage-based nanoparticle platform for antiretroviral drug delivery. Blood 108(8), 2827-2835 (2006).
17. Seguin R, Biernacki K, Rotondo RL, Prat A, Antel JP: Regulation and functional effects of monocyte migration across human brain-derived endothelial cells. J. Neuropathol. Exp. Neurol. 62(4), 412-419 (2003). (Pubitemid 36403041)
18. Zelivyanskaya ML, Nelson JA, Poluektova L et al.: Tracking superparamagnetic iron oxide labeled monocytes in brain by high-field magnetic resonance imaging. J. Neurosci. Res. 73(3), 284-295 (2003). (Pubitemid 36918092)
19. Weidenfeller C, Schrot S, Zozulya A, Galla HJ: Murine brain capillary endothelial cells exhibit improved barrier properties under the influence of hydrocortisone. Brain Res. 1053(1-2), 162-174 (2005). (Pubitemid 41116802)
20. Batrakova E, Han H, Miller D, Kabanov A: Effects of pluronic p85 unimers and micelles on drug permeability in polarized bbmec and caco-2 cells. Pharm. Res. 15(10), 1525-1532 (1998). (Pubitemid 28465737)
21. Batrakova E, Li S, Miller D, Kabanov A: Pluronic p85 increases permeability of a broad spectrum of drugs in polarized BBMEC and caco-2 cell monolayers. Pharm. Res. 16(9), 1366-1372 (1999). (Pubitemid 29449372)
22. Benner EJ, Mosley RL, Destache CJ et al.: Therapeutic immunization protects dopaminergic neurons in a mouse model of Parkinson's disease. Proc. Natl Acad. Sci. USA 101(25), 9435-9440 (2004). (Pubitemid 38812892)
23. Jackson-Lewis V, Przedborski S: Protocol for the mptp mouse model of Parkinson's disease. Nat. Protoc. 2(1), 141-151 (2007). (Pubitemid 47044700)
24. Tieu K, Perier C, Caspersen C et al.: d-b-hydroxybutyrate rescues mitochondrial respiration and mitigates features of Parkinson disease. J. Clin. Invest. 112(6), 892-901 (2003). (Pubitemid 38063747)
25. Liberatore GT, Jackson-Lewis V, Vukosavic S et al.: Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease. Nat. Med. 5(12), 1403-1409 (1999).
26. Boska MD, Lewis TB, Destache CJ et al.: Quantitative 1H magnetic resonance spectroscopic imaging determines therapeutic immunization efficacy in an animal model of Parkinson's disease. J. Neurosci. 25(7), 1691-1700 (2005).
27. Hetherington HP, Pan JW, Mason GF et al.: 2D 1H spectroscopic imaging of the human brain at 4.1 T. Magn. Reson. Med. 32(4), 530-534 (1994). (Pubitemid 24307982)
28. Glass JD, Fedor H, Wesselingh SL, McArthur JC: Immunocytochemical quantitation of human immunodeficiency virus in the brain: correlations with dementia. Ann. Neurol. 38(5), 755-762 (1995).
29. Liu B, Hong JS: Role of microglia in inflammation-mediated neurodegenerative diseases: mechanisms and strategies for therapeutic intervention. J. Pharmacol. Exp. Ther. 304(1), 1-7 (2003). (Pubitemid 36008905)
30. Stone DK, Reynolds AD, Mosley RL, Gendelman HE: Innate and adaptive immunity for the pathobiology of Parkinson's disease. Antioxid. Redox Signal 11(9), 2151-2166 (2009).
31. Ebadi M, Srinivasan SK, Baxi MD: Oxidative stress and antioxidant therapy in Parkinson's disease. Prog. Neurobiol. 48(1), 1-19 (1996). (Pubitemid 26111215)
32. Wu DC, Teismann P, Tieu K et al.: NADPH oxidase mediates oxidative stress in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. Proc. Natl Acad. Sci. USA 100(10), 6145-6150 (2003). (Pubitemid 36576945)
33. Navarro A, Boveris A: Brain mitochondrial dysfunction and oxidative damage in Parkinson's disease. J. Bioenerg. Biomembr. 41(6), 517-521 (2009).
34. Zarkovic N: 4-hydroxynonenal as a bioactive marker of pathophysiological processes. Mol. Aspects Med. 24(4-5), 281-291 (2003). (Pubitemid 36945028)
35. Mcgeer PL, Itagaki S, Boyes BE, McGeer EG: Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology 38(8), 1285-1291 (1988).
36. Busciglio J, Yankner BA: Apoptosis and increased generation of reactive oxygen species in Down's syndrome neurons in vitro. Nature 378(6559), 776-779 (1995). (Pubitemid 26004408)
37. Boje KM, Arora PK: Microglial-produced nitric oxide and reactive nitrogen oxides mediate neuronal cell death. Brain Res. 587(2), 250-256 (1992).
38. Chao CC, Hu S, Molitor TW, Shaskan EG, Peterson PK: Activated microglia mediate neuronal cell injury via a nitric oxide mechanism. J. Immunol. 149(8), 2736-2741 (1992).
39. Mcguire SO, Ling ZD, Lipton JW, Sortwell CE, Collier TJ, Carvey PM: Tumor necrosis factor a is toxic to embryonic mesencephalic dopamine neurons. Exp. Neurol. 169(2), 219-230 (2001).
40. Whitton PS: Inflammation as a causative factor in the aetiology of Parkinson's disease. Br. J. Pharmacol. 150(8), 963-976 (2007). (Pubitemid 46628616)
41. Simone EA, Dziubla TD, Colon-Gonzalez F, Discher DE, Muzykantov VR: Effect of polymer amphiphilicity on loading of a therapeutic enzyme into protective filamentous and spherical polymer nanocarriers. Biomacromolecules 8(12), 3914-3921 (2007).
42. Siwale RC, Oettinger CW, Balakrishna Pai S et al.: Formulation and characterization of catalase in albumin microspheres. J. Microencapsul. 1-9 (2008).
43. Prasad KN, Cole WC, Hovland AR et al.: Multiple antioxidants in the prevention and treatment of neurodegenerative disease: analysis of biologic rationale. Curr. Opin. Neurol. 12(6), 761-770 (1999).
44. Beal MF, Matthews RT: Coenzyme q10 in the central nervous system and its potential usefulness in the treatment of neurodegenerative diseases. Mol. Aspects Med. 18(Suppl.) S169-S179 (1997). (Pubitemid 27372933)
45. Zhao K, Luo G, Giannelli S, Szeto HH: Mitochondria-targeted peptide prevents mitochondrial depolarization and apoptosis induced by tert-butyl hydroperoxide in neuronal cell lines. Biochem. Pharmacol. 70(12), 1796 - 1806 (2005). (Pubitemid 41612010)
46. Dou H, Grotepas CB, McMillan JM et al.: Macrophage delivery of nanoformulated antiretroviral drug to the brain in a murine model of neuroaids. J. Immunol. 183(1), 661-669 (2009).
47. Hendriks JJ, Teunissen CE, De Vries HE, Dijkstra CD: Macrophages and neurodegeneration. Brain Res. Rev. 48(2), 185-195 (2005).
48. Langston JW, Irwin I: MPTP: current concepts and controversies. Clin. Neuropharmacol. 9(6), 485-507 (1986). (Pubitemid 17217320)
49. Langston JW, Forno LS, Tetrud J, Reeves AG, Kaplan JA, Karluk D: Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure. Ann. Neurol. 46(4), 598-605 (1999). (Pubitemid 29466438)
50. Schmidt N, Ferger B: Neurochemical findings in the MPTP model of Parkinson's disease. J. Neural Transm. 108(11), 1263-1282 (2001). (Pubitemid 33141302)
51. Kokovay E, Cunningham LA: Bone marrow-derived microglia contribute to the neuroinflammatory response and express INOS in the MPTP mouse model of Parkinson's disease. Neurobiol. Dis. 19(3), 471-478 (2005). (Pubitemid 40968060)
52. Mosley R, Benner E, Kadiu I et al.: Neuroinflammation, oxidative stress, and the pathogenesis of Parkinson's disease. Clin. Neurosci. Res. 6(5), 261-281 (2006). (Pubitemid 44849177)
53. Audoy-Remus J, Richard JF, Soulet D, Zhou H, Kubes P, Vallieres L: Rod-shaped monocytes patrol the brain vasculature and give rise to perivascular macrophages under the influence of proinflammatory cytokines and angiopoietin-2. J. Neurosci. 28(41), 10187-10199 (2008).